Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: collegiumpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $58.00 | Overweight | Barclays |
| 1/10/2025 | $46.00 | Hold → Buy | Needham |
| 7/30/2024 | $47.00 | Neutral → Buy | H.C. Wainwright |
| 6/7/2024 | $41.00 → $44.00 | Hold → Buy | Jefferies |
| 5/10/2024 | Buy → Hold | Needham | |
| 5/10/2024 | $39.00 | Overweight → Neutral | Piper Sandler |
| 1/4/2024 | $30.00 → $37.00 | Buy → Hold | Jefferies |
| 8/25/2023 | $35.00 → $36.00 | Buy | Needham |
| 5/2/2023 | $30.00 | Buy | Jefferies |
| 8/8/2022 | Buy → Neutral | H.C. Wainwright |
Fastest customizable press release news feed in the world
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. Details of the event are as follows: Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ETNew York, NY A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Collegium Pharmaceutical, Inc.Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition – – 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million – STOUGHTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced that it has completed the acquisition of AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a cent
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., May 07
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2026 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Comp
STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual Healthcare ConferenceFireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m. ETVirtual A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Piper Sandler Spring Biopharma SymposiumThursday, April 16, 2026Boston, MA About Collegium Pharmaceutical, Inc.Collegium is building
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue – – Expected Patent Protection into 2037 – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition to Be Funded by Collegium's Cash on Hand and Previously Announced $300 Million Delayed Draw Term Loan – – Conference Call Scheduled for Today at 9:00 a.m. ET – STOUGHTON, Mass. and CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) a
STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium's pain portfolio and reflect the Company's continued focus on generating evidence that helps inform everyday practice. "Understanding how therapies perform in real-world settings is essential to informing pain treatment," said Thomas Smith, M.D., Chief Med
– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan – Credit: Ashley Osborn STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, and Paris Hilton, an entrepreneur, musician, author, and advocate, announced today ‘Embrace Your Sparkle', a campaign aimed at encouraging broader understanding and open dialogue about at
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026Miami, FL Jefferies Biotech on the Beach SummitTuesday, March 10, 2026Miami, FL The Citizens Life Sciences ConferenceTuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ETMiami, FL A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webc
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents, and Marketable Securities of $386.7 Million – – Reaffirmed Full-Year 2026 Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Feb. 26,
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays initiated coverage of Collegium Pharmaceutical with a rating of Overweight and set a new price target of $58.00
Needham upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $46.00
H.C. Wainwright upgraded Collegium Pharmaceutical from Neutral to Buy and set a new price target of $47.00
Jefferies upgraded Collegium Pharmaceutical from Hold to Buy and set a new price target of $44.00 from $41.00 previously
Needham downgraded Collegium Pharmaceutical from Buy to Hold
Piper Sandler downgraded Collegium Pharmaceutical from Overweight to Neutral and set a new price target of $39.00
Jefferies downgraded Collegium Pharmaceutical from Buy to Hold and set a new price target of $37.00 from $30.00 previously
Needham reiterated coverage of Collegium Pharmaceutical with a rating of Buy and set a new price target of $36.00 from $35.00 previously
Jefferies resumed coverage of Collegium Pharmaceutical with a rating of Buy and set a new price target of $30.00
H.C. Wainwright downgraded Collegium Pharmaceutical from Buy to Neutral
S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
S-8 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SCHEDULE 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
144 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SCHEDULE 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
10-Q - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
8-K - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
3 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
4 - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Issuer)
Live finance-specific insights
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition – – 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million – STOUGHTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced that it has completed the acquisition of AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a cent
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., May 07
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2026 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Comp
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue – – Expected Patent Protection into 2037 – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition to Be Funded by Collegium's Cash on Hand and Previously Announced $300 Million Delayed Draw Term Loan – – Conference Call Scheduled for Today at 9:00 a.m. ET – STOUGHTON, Mass. and CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) a
– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents, and Marketable Securities of $386.7 Million – – Reaffirmed Full-Year 2026 Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Feb. 26,
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q4 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available fo
– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3'25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Nov. 06, 2025 (GLOBE NEW
STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q3 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the
– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million – – Ended Q2'25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million – – Board of Directors Authorized $150 Million Share Repurchase
STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q2 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the C
This live feed shows all institutional transactions in real time.
SC 13G - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
SC 13G/A - COLLEGIUM PHARMACEUTICAL, INC (0001267565) (Subject)
Live Leadership Updates
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company, today announced updates to its Board of Directors and appointments of three new executive leaders as the C
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. "Collegium is pleased to welcome Nancy to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions." "This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth
STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that Vikram Karnani has been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Directors effective November 12, 2024. Michael Heffernan, who has served as Interim President and CEO since May 2024, will remain Chairman of the Board. Mr. Karnani has more than 15 years of leadership experience in the life sciences industry. Over the course of nearly a decade at Horizon Therapeutics, Mr. Karnani he
– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that effective May 24, 2024, Joe Ciaffoni will step down as President and Chief Executive Officer (CEO) of the Company. Mr. Ciaffoni will serve as a member of the Board of Directors of the Company until the
STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. "Collegium is delighted to welcome Neil to our Board of Directors," said Mike Heffernan, Founder and Chairman of the Board of Collegium. "Neil's track record of successful leadership and industry experience will be tremendously valuable for the Company. We are confident that Collegium will benefit from his insights, and we look forward to Neil's meaningful contributions to our Board of Directors." "This is a very important and exci
– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta® Franchise and Adjusted EBITDA 2021 Guidance Range Raised – – Colleen Tupper Appointed as Next CFO; Paul Brannelly will be Leaving the Company to Pursue Other Opportunities – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update. The company also announced the appointme